止血药物给药时间延长增加因Xa因子抑制剂相关颅内出血退伍军人死亡率
该研究为退伍军人健康管理局2018年1月1日至2024年1月1日的全国回顾性队列,纳入246例因Xa因子抑制剂相关颅内出血接受安德昔单抗α(n=89)或四因子凝血酶原复合物(n=157)治疗的退伍军人。主要终点止血治疗时间两组无差异(安德昔单抗α中位203分钟 vs 四因子凝血酶原复合物中位200分钟,p=0.70)。90天死亡率为19.1%,止血药物给药时间每增加1分钟,90天死亡几率增加0.4%(OR 1.004,95%CI 1.001-1.006)。结论提示缩短止血药物给药时间可能改善结局,但两种药物选择无差异。
要点
- 在因Xa因子抑制剂相关颅内出血的退伍军人中,安德昔单抗α与四因子凝血酶原复合物止血治疗时间无差异(中位203分钟 vs 200分钟,p=0.70)。
- 止血药物给药时间每延迟1分钟,90天死亡几率增加0.4%(OR 1.004,95%CI 1.001-1.006)。
- 90天死亡率为19.1%,绝大多数患者为男性(96.4%)且高龄。
- 阿哌沙班是最常用的抗凝药,脑内出血是最常见的颅内出血类型。
- 该研究为回顾性队列,样本量较小(246例),需进一步研究验证。
适用人群与场景
- 退伍军人健康管理局数据库中,2018年1月1日至2024年1月1日期间在急诊科就诊前180天内使用过Xa因子抑制剂并发生颅内出血的退伍军人。
- 纳入246例接受安德昔单抗α或四因子凝血酶原复合物治疗的患者;排除标准未明确报告。
研究设计与关键结果
- 研究类型:全国回顾性队列,样本量246例(安德昔单抗α组89例,四因子凝血酶原复合物组157例),人群为退伍军人健康管理局中因Xa因子抑制剂相关颅内出血的退伍军人。
- 主要终点:止血治疗时间两组无差异(安德昔单抗α组中位203分钟,IQR 140-283 vs 四因子凝血酶原复合物组中位200分钟,IQR 137-299,p=0.70)。
- 关键次要终点:90天死亡率为19.1%;止血药物给药时间每增加1分钟,90天死亡几率增加0.4%(OR 1.004,95%CI 1.001-1.006)。
- 其他结果:大多数患者为男性(96.4%)且高龄;阿哌沙班是最常用的抗凝药;脑内出血是最常见的颅内出血类型。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因Xa因子抑制剂相关颅内出血的退伍军人,安德昔单抗α与四因子凝血酶原复合物在止血治疗时间上无差异。
- 止血药物给药时间每延迟1分钟,90天死亡几率增加0.4%,提示应尽可能缩短给药时间。
- 两种止血药物选择对90天死亡几率的影响无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The two hemostatic agents utilized for reversal of life-threatening hemorrhage associated with Factor Xa (fXa) inhibition are andexanet alfa (AA) and four-factor prothrombin complex concentrate (4F-PCC). In May 2018, AA was approved with possible superior short-term hemostatic efficacy but has been linked with higher rates of thrombotic events. Considering these concerns, the absence of high-quality comparative studies, and the higher cost compared to other agents, four-factor prothrombin complex concentrate remained the more utilized agent. There is a critical need for real-world data from large-scale databases describing the reversal of fXa inhibitors using AA compared to 4F-PCC to determine their time to hemostatic treatment and its effect on patient outcomes and mortality.
METHODS: This was a national retrospective cohort from the Veteran Health Administration of AA or 4 F-PCC usage between January 1, 2018 to January 1, 2024. The primary endpoint was time to hemostatic treatment. The secondary endpoints were 30-day thrombotic events and 90-day mortality, which were validated through manual chart review. Demographic and treatment variables were summarized using descriptive statistics. The two sample Wilcoxon rank-sum test was utilized on the primary endpoint. A multivariable logistic regression was used to analyze the relationship between 90-day mortality and time to hemostatic treatment.
RESULTS: There were 19,015 Veterans with ICH; 246 (AA n = 89; 4F-PCC n = 157) of the Veterans that received an fXa inhibitor within 180 days in the emergency department were included in the study. Most Veterans were male (96.4 %) and elderly. Apixaban was the most utilized anticoagulant, and intracerebral hemorrhage was the most common type of intracranial hemorrhage (ICH). There was no difference in the primary endpoint of time to hemostatic treatment between the groups (AA group median: 203 min (IQR 140-283) vs. 4F-PCC median: 200 min (IQR 137-299), p = 0.70). 90-day mortality was 19.1 % where the odds of 90-day mortality increased by 0.4 % for each additional minute of time to hemostatic agent administration (odds ratio [OR] 1.004, 95 % confidence interval ([CI] 1.001-1.006).
CONCLUSION: In Veterans with fXa inhibitor-related ICH receiving AA or 4F-PCC, there was no difference between AA and 4F-PCC in time to hemostatic treatment. Time to hemostatic agent administration increased odds of 90-mortality by 0.4 % for every minute, but did not differ depending on the hemostatic agent used.
参考来源
- Markovic N, Budde E, Evans CT, et al. Time to hemostatic agent administration increases mortality in veterans with factor Xa inhibitor-related intracranial hemorrhage. Am J Emerg Med. 2025. PMID: 40907273. doi:10.1016/j.ajem.2025.08.047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。